Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q4 FY24 results · Jan–Mar 2024
Panacea Biotec reported revenue from operations of ₹136.46 crore (up 5.8% from Q4 FY23) and net loss of ₹1.99 crore for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 136.46 | 128.93 | +5.8% | 150.50 | −9.3% |
| Other income | 10.81 | 15.06 | −28.2% | 5.68 | +90.3% |
| Total income | 147.27 | 143.99 | +2.3% | 156.18 | −5.7% |
| Profit before tax | (2.12) | 18.21 | Turned loss | (1.65) | Loss widened |
| Net profit for the period | (1.99) | (12.68) | Loss narrowed | (2.20) | Loss narrowed |
| Attributable to shareholders of the company | (1.43) | — | — | — | — |
| EPS, basic (₹) | (0.23) | (2.07) | Loss narrowed | (0.37) | Loss narrowed |
| Net margin (%) | -1.5 | -9.8 | -1.5 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 80.37 | 75.02 | +7.1% | 95.23 | −15.6% |
| Other income | 16.39 | 10.27 | +59.6% | 3.05 | +437.4% |
| Total income | 96.76 | 85.29 | +13.4% | 98.28 | −1.5% |
| Profit before tax | (1.35) | 5.10 | Turned loss | 1.07 | Turned loss |
| Net profit for the period | (1.37) | (19.69) | Loss narrowed | 0.43 | Turned loss |
| EPS, basic (₹) | (0.22) | (3.21) | Loss narrowed | 0.07 | Turned loss |
| Net margin (%) | -1.7 | -26.2 | 0.5 |
Consolidated
- Filed with BSE
- 19 Jul 2024, 17:08 IST
- Board meeting
- 30 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 19 Jul 2024, 17:08 IST
- Board meeting
- 30 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE